Placeholder

Ibritumomab Tiuxetan

CAS No:
206181-63-7 Categories: , , ,
  • # LGM Pharma is a Ibritumomab Tiuxetan CAS# 206181-63-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ibritumomab Tiuxetan
  • CAS #: 206181-63-7
  • Mode of Action:

    The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.

  • Pharmacodynamics:

    Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.

  • Metabolism:

    Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production

  • IUPAC: Immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDEC-Y2B8 gamma1-chain), disulfide with mouse monoclonal IDEC-Y2B8 kappa-chain, dimer, N-(2-(bis(carboxymethyl)amino)-3-(4-isothiocyanatophenyl)propyl)-N-(2-(bis(carboxymethyl)amino)propyl)glycine conjugate
  • DrugBank: DB00078
  • Molecular Mass: 570.5968
  • Synonyms: BAY 86-5128, BAY86-5128, Ibritumomab, Ibritumomab tiuxetan, IDEC-129, IDEC-Y2B8, Immunoglobulin G1 (mouse monoclonal IDEC-Y2B8 gamma1-chain anti-human antigen CD20), disulfide with mouse monoclonal IDEC-Y2B8 K-chain, dimer, N-(2-(bis(carboxymethyl)amino)-3-(p-isothiocyanatophenyl)propyl)-N-(2-(bis(carboxymethyl)amino)propyl)glycine conjugate. Molecular weight is approximately 1500 daltons, SHL 749, UNII-4Q52C550XK, Zevalin
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

Click here to read our press release
This website uses cookies. By using our site, you agree to our terms of service